A phase I combination study of irofulven (IROF) and gemcitabine (GEM) in patients (pts) with advanced solid malignancies.

被引：0
|
作者：
O'Bryant, CL
Gore, L
Long, M
Gustafson, D
Eppers, S
Basche, M
Rothenberg, M
Weems, G
Shah, A
Herdrich, L
Eckhardt, SG
Berlin, J
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] MGI Pharma Inc, Bloomington, IN USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9119S / 9120S
页数：2
相关论文
共 50 条
  • [1] Phase I study of RFS 2000 and gemcitabine (Gem) in patients with advanced malignancies.
    Fracasso, PM
    Tan, BR
    Sun, SL
    Revell, SM
    Lenaz, L
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4515S - 4515S
  • [2] Phase I And pharmacokinetic study of irofulven (IROF) in combination with cisplatin (CDDP), given every 2 weeks, in patients (pts) with advanced solid tumors.
    Hilgers, W
    Alexandre, J
    Tourani, JM
    Misset, JL
    Goldwasser, F
    Bourgeois, H
    Faivre, S
    Kahatt, C
    Cvitkovic, E
    Weems, G
    Raymond, E
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6080S - 6080S
  • [3] A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer
    Arkenau, H.
    Evans, J.
    Lokelma, M.
    Roxburgh, P.
    Morisson, R.
    Coffey, M.
    Gill, G.
    Mettinger, K.
    Thompson, B.
    de Bono, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Phase I trial of gemcitabine and epirubicin in patients with solid malignancies.
    Mahadevan, D
    Dreisbach, L
    Williams, D
    Pilkington, D
    Gebremarium, C
    Martin, E
    Obregon, Y
    Von Hoff, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 360S - 360S
  • [5] A phase I Study of ecteinascidin 743(E) and capecitabine (C) in patients (pts) with advanced solid malignancies.
    Holden, SN
    Rivera, E
    Basche, M
    Gore, L
    Raj, SKS
    O'Bryant, CL
    Grolnic, S
    Hunt, J
    Brillhart, B
    Van de Velde, H
    Roberts, D
    Rodgers, J
    Eckhardt, SG
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6080S - 6080S
  • [6] Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies
    Haigentz, M
    Kim, M
    Sorich, J
    Lee, J
    Hochster, H
    Macapinlac, M
    Mirchandani, D
    Sewak, S
    Pavlick, A
    Volm, M
    Hamilton, A
    Muggia, FM
    [J]. ANTI-CANCER DRUGS, 2003, 14 (04) : 321 - 326
  • [7] Phase I study of vandetinib in combination with gemcitabine and oxaliplatin in advanced solid malignancies
    Wang, Peng
    Owonikoko, Taofeek Kunle
    Lin, Yan
    Stoller, Ronald G.
    Petro, Daniel P.
    Park, Deric M.
    Ramanathan, Ramesh K.
    Chu, Edward
    Beumer, Jan Hendrik
    Appleman, Leonard Joseph
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies.
    Anderson, S
    Dizon, D
    Sabbatini, P
    Dupont, J
    Pezzulli, S
    Massey, A
    Aghajanian, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 151S - 151S
  • [9] Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies.
    Dupont, J
    Schwartz, L
    Koutcher, J
    Spriggs, D
    Gordon, M
    Mendelson, D
    Murren, J
    Lucarelli, A
    Cedarbaum, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 197S - 197S
  • [10] Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.
    Sausville, E. A.
    LoRusso, P.
    Carducci, M. A.
    Barker, P. N.
    Agbo, F.
    Oakes, P.
    Senderowicz, A. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345